Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-01-16
2009-10-20
Gabel, Gailene R (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S007930, C435S007940, C435S007950, C435S967000, C435S973000, C436S540000, C436S546000, C436S548000, C436S013000, C436S015000, C436S071000, C436S517000, C436S819000
Reexamination Certificate
active
07604952
ABSTRACT:
A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.
REFERENCES:
patent: 4444879 (1984-04-01), Foster et al.
patent: 5024829 (1991-06-01), Berger et al.
patent: 5026537 (1991-06-01), Daddona et al.
patent: 5046499 (1991-09-01), Berger
patent: 5120834 (1992-06-01), Gargan et al.
patent: 5196324 (1993-03-01), Bumol et al.
patent: 5223410 (1993-06-01), Gargan et al.
patent: 5362649 (1994-11-01), Schwertner
patent: 5380667 (1995-01-01), Schwertner
patent: 5396886 (1995-03-01), Cuypers
patent: 5453359 (1995-09-01), Gargan et al.
patent: 5487892 (1996-01-01), Gargan
patent: 5597726 (1997-01-01), Bumol et al.
patent: 5604105 (1997-02-01), Jackowski
patent: 5658729 (1997-08-01), Hayden
patent: 5690103 (1997-11-01), Groth et al.
patent: 5710008 (1998-01-01), Jackowski
patent: 5756067 (1998-05-01), Redgrave et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6309888 (2001-10-01), Holvoet et al.
patent: 6727102 (2004-04-01), Holvoet et al.
patent: 7166469 (2007-01-01), Holvoet et al.
patent: 7229775 (2007-06-01), Holvoet et al.
patent: 7390627 (2008-06-01), Holvoet et al.
patent: 2003/0100486 (2003-05-01), Ridker et al.
patent: 2003/0152566 (2003-08-01), Schonbeck et al.
patent: 0 484 863 (1992-05-01), None
patent: 0 433 088 (1997-06-01), None
patent: 4-173096 (1992-06-01), None
patent: KOKAI 8-304395 (1996-11-01), None
patent: KOKAI 9-5323 (1997-10-01), None
patent: WO 94/23302 (1994-10-01), None
patent: PCT/EP97/03287 (1997-06-01), None
patent: PCT/EP97/03493 (1997-07-01), None
patent: WO 98/59248 (1998-12-01), None
Holvoet et al., OxidizedLow Density Lipoproteins In Patients With Transplant-Associated Coronary Artery Disease, Arterioscler. Thromb. Vasc. Biol. 18(1): 100-107 (Jan. 1998).
Holvoet et al., Malondialdehyde-Modified Low Density Lipoproteins In Patients With Atherosclerotic Disease, J. Clin. Invest. 95: 2611-2619 (1995).
Holvoet et al., “Association Between Circulating Oxidized Low-Density Lipoprotein And Incidence Of The Metabolic Syndrome,” JAMA, vol. 299, No. 19, pp. 2287-2293 (May 21, 2008)(available at JAMA website on May 20, 2008).
Adams JE, 3d, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. “Cardiac Troponin I. A Marker With High Specificity For Cardiac Injury,”Circulation. 1993; 88(1): 101-106.
American Biogenetic Sciences Inc.1995 Annual Report. 24 pages (1995).
American Biogenetic Sciences. Focus on Diagnostic Tests: A Technology Anaylsis. Updated Full Report. 33 pages. Paisley and Habermas, Inc. (Jun. 3, 1996).
American Biogenetic Sciences, Inc., “Renal dialysis joint venture announced by American Biogenetic Sciences, Inc. and Gull Laboratories, Inc.” News Release (Sep. 26, 1996).
American Biogenetic Sciences, Inc. Jesup & Lamont Securities Corporation, “New Buy Recommendation dated Mar. 28, 1996” (12 pages.).
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. “Cardiac-Specific Troponin I Levels To Predict The Risk Of Mortality In Patients With Acute Coronary Syndromes.”N. Eng. J. Med. 1996; 335(18): 1342-1349.
AtheroGenics, Inc. Printout of Web Site (www.atherogenics.com). Home page and “Technology Platform” and “In The News” sections. 17 pages (printed Jun. 8, 1998).
Aviram M, Maor I. “Phospholipase D-Modified Low Density Lipoprotein Is Taken Up By Macrophages At Increased Rate. A Possible Role For Phosphatidic Acid.”J. Clin. Invest. 1993; 91: 1942-1952.
Berliner JA, Heinecke JW. “The Role Of Oxidized Lipoproteins In Atherogenesis,”Free Radical Biology&Medicine1996; 20(5): 707-727.
Brown MS, Goldstein JL. “Lipoprotein Metabolism In the Macrophage: Implications For Cholesterol Deposition In Atherosclerosis.”Annu. Review Biochem. 1983; 52: 223-261.
Cartier R, Dagenais F, Hollmann C, Cambron H, Buluran J. “Chronic Exposure To Cyclosporin Affects Endothelial And Smooth Muscle Reactivity In The Rat Aorta.”Ann. Thorac. Surg. 1994; 58: 789-794.
Chen CH, Nguyen HH, Weilbaecher D, Luo S, Gotto Jr. AM, Henry PD. “Basic Fibroblast Growth Factor Reverses Atherosclerotic Impairment Of Human Coronary Angiogenesis-Like Responses In Vitro.”Atherosclerosis1995; 116: 261-268.
Chin JH, Azhar S, Hoffman BB. “Inactivation Of Endothelial Derived Relaxing Factor By Oxidized Lipoproteins.”J. Clin. Invest. 1992; 89: 10-18.
Cockcroft DW, Gault MH. “Prediction of creatinine clearance from serum creatinine.”Nephron1976; 16: 31-41.
Crisp SJ, Dunn JM, Rose ML, Barbir M, Yacoub MH. “Antiendothelial Antibodies After Heart Transplantation: The Accelerating Factor In Transplant-Associated Coronary Artery Disease?”J. Heart Lung Transplant. 1994; 13(1, Part 1): 81-92.
Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. “Fibrinolytic Response And Fibrin Fragment D-Dimer Levels In Patients With Deep Vein Thrombosis.”Thromb. Haemost. 1987; 58(4): 1024-1029.
Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C. “Mortality Risk Factors In Patients Treated By Chronic Hemodialysis.”Nephron1982; 31: 103-110.
Esterbauer H, Jurgens G, Quehenberger Q, Koller E. “Autooxidation Of Human Low Density Lipoprotein: Loss Of Polyunsaturated Fatty Acids And Vitamin E And Generation Of Aldehydes.”J. Lipid Res.. 1987; 28: 495-509.
Farber HW, Barnett HF. “Differences In Prostaglandin Metabolism In Cultured Aortic And Pulmonary Arterial Endothelial Cells Exposed To Acute And Chronic Hypoxia.”Circ. Res. 1991; 68(5): 1446-1457.
Fogelman MA, Shechter, I, Seager J, Hokom M, Child JS, Edwards PA. “Malondialdehyde Alteration Of Low Density Lipoproteins Leads To Cholesteryl Ester Accumulation In Human Monocyte-Macrophages.”Proc. Natl. Acad. Sci. USA1980; 77(4): 2214-2218.
Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. “Lipoxygenase Contributes To The Oxidation Of Lipids In Human Atherosclerotic Plaques.”J. Clin. Invest. 1995; 96: 504-510.
Friedman JA, Dwyer JT. “Hyperhomocysteinemia As A Risk Factor For Cardiovascular Disease In Patients Undergoing Hemodialysis.”Nutr. Rev. 1995; 53(7): 197-201.
Galle J, Bengen J, Schollmeyer P, Wanner C. “Oxidized Lipoprotein(A) Inhibits Endothelium-Dependent Dilation: Prevention By High Density Lipoprotein.”Eur. J. Pharmacol. 1994; 265: 111-115.
Galle J, Schollmeyer P, Wanner C. “Cyclosporin And Oxidized Low Density Lipoproteins Synergistically Potentiate Vasoconstriction: Influence Of The Endothelium.”Eur. Heart J. 1993; 14(Suppl. I): 111-117.
Gerrity RG. “The Role Of The Monocyte In Atherogenesis. I. Transition Of Blood-Borne Mo
Collen Désiré J.
Holvoet Paul N.
Bryan Cave LLP
Gabel Gailene R
Gilbert, Esq. Stephen P.
Leuven Research & Development VZW
LandOfFree
Detection and determination of the stages of coronary artery... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection and determination of the stages of coronary artery..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection and determination of the stages of coronary artery... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061856